“6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry”, J of Skin, vol. 7, no. 6, p. s232, Nov. 2023, doi: 10.25251/skin.7.supp.232.